Cogent Biosciences Announces 2024 Annual Meeting of Stockholders on June 5
Ticker: COGT · Form: DEF 14A · Filed: Apr 23, 2024 · CIK: 1622229
| Field | Detail |
|---|---|
| Company | Cogent Biosciences, INC. (COGT) |
| Form Type | DEF 14A |
| Filed Date | Apr 23, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $12,500 |
| Sentiment | neutral |
Sentiment: neutral
Topics: Proxy Statement, Annual Meeting, Shareholder Vote, Executive Compensation, Authorized Shares
TL;DR
<b>Cogent Biosciences is holding its 2024 Annual Meeting on June 5, 2024, to vote on director elections, auditor ratification, executive compensation, and a significant increase in authorized shares.</b>
AI Summary
Cogent Biosciences, Inc. (COGT) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. Cogent Biosciences will hold its 2024 Annual Meeting of Stockholders on June 5, 2024, at 9:00 a.m. ET. The meeting will be conducted virtually via live audio webcast. Key agenda items include electing two Class III director nominees, ratifying PricewaterhouseCoopers LLP as independent auditors for FY2024, and approving executive compensation. Stockholders will also vote on the frequency of future executive compensation advisory votes. A proposal to amend the Certificate of Incorporation to increase authorized common stock from 150,000,000 to 300,000,000 shares will be presented.
Why It Matters
For investors and stakeholders tracking Cogent Biosciences, Inc., this filing contains several important signals. The proposed increase in authorized shares from 150 million to 300 million could signal future capital-raising needs or stock-based compensation plans. The annual meeting is a critical governance event where shareholders have a say in board composition, auditor selection, and executive pay, influencing the company's strategic direction and accountability.
Risk Assessment
Risk Level: low — Cogent Biosciences, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting with no immediate financial or operational news, indicating low immediate risk.
Analyst Insight
Review the proposals, particularly the increase in authorized shares and executive compensation, to understand potential future dilution or governance implications.
Key Numbers
- June 5, 2024 — Annual Meeting Date (2024 Annual Meeting of Stockholders)
- 9:00 a.m. Eastern Time — Annual Meeting Time (2024 Annual Meeting of Stockholders)
- April 10, 2024 — Record Date (Stockholders of record on this date are entitled to vote)
- 150,000,000 — Current Authorized Shares (Common stock)
- 300,000,000 — Proposed Authorized Shares (Common stock)
Key Players & Entities
- Cogent Biosciences, Inc. (company) — Registrant
- PricewaterhouseCoopers LLP (company) — Independent registered public accounting firm
- June 5, 2024 (date) — Date of Annual Meeting
- April 10, 2024 (date) — Record date for the Annual Meeting
- 150,000,000 (dollar_amount) — Current authorized shares
- 300,000,000 (dollar_amount) — Proposed authorized shares
FAQ
When did Cogent Biosciences, Inc. file this DEF 14A?
Cogent Biosciences, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 23, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Cogent Biosciences, Inc. (COGT).
Where can I read the original DEF 14A filing from Cogent Biosciences, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Cogent Biosciences, Inc..
What are the key takeaways from Cogent Biosciences, Inc.'s DEF 14A?
Cogent Biosciences, Inc. filed this DEF 14A on April 23, 2024. Key takeaways: Cogent Biosciences will hold its 2024 Annual Meeting of Stockholders on June 5, 2024, at 9:00 a.m. ET.. The meeting will be conducted virtually via live audio webcast.. Key agenda items include electing two Class III director nominees, ratifying PricewaterhouseCoopers LLP as independent auditors for FY2024, and approving executive compensation..
Is Cogent Biosciences, Inc. a risky investment based on this filing?
Based on this DEF 14A, Cogent Biosciences, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting with no immediate financial or operational news, indicating low immediate risk.
What should investors do after reading Cogent Biosciences, Inc.'s DEF 14A?
Review the proposals, particularly the increase in authorized shares and executive compensation, to understand potential future dilution or governance implications. The overall sentiment from this filing is neutral.
Risk Factors
- Compliance with SEC Regulations [low — regulatory]: The company must comply with all SEC rules and regulations regarding proxy solicitations and annual meetings.
- Shareholder Approval for Share Increase [low — financial]: The proposed increase in authorized shares requires shareholder approval and could impact future equity financing.
- Virtual Meeting Logistics [low — operational]: Ensuring a smooth and accessible virtual meeting experience for all shareholders is crucial.
Key Dates
- 2024-06-05: 2024 Annual Meeting of Stockholders — Key date for shareholder voting on proposals.
- 2024-04-10: Record Date — Determines which shareholders are eligible to vote.
Glossary
- Proxy Statement
- A document filed with the SEC that provides shareholders with information about matters to be voted on at a company's annual meeting. (Provides essential details for shareholders to make informed voting decisions.)
Filing Stats: 4,740 words · 19 min read · ~16 pages · Grade level 12.5 · Accepted 2024-04-23 16:32:57
Key Financial Figures
- $12,500 — t us in soliciting proxies for a fee of $12,500 plus distribution costs and other expen
Filing Documents
- d675436ddef14a.htm (DEF 14A) — 429KB
- g675436dsp001ajpg.jpg (GRAPHIC) — 8KB
- g675436dspp004a.jpg (GRAPHIC) — 3KB
- g675436dspp004b.jpg (GRAPHIC) — 3KB
- g675436g45t78.jpg (GRAPHIC) — 45KB
- g675436g75x49.jpg (GRAPHIC) — 76KB
- g675436g84s56.jpg (GRAPHIC) — 73KB
- 0001193125-24-107124.txt ( ) — 711KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 28 CERTAIN INFORMATION ABOUT OUR COMMON STOCK 36 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 40 OTHER MATTERS 43 LEGAL MATTERS Important Notice Regarding the Availability of Proxy Materials for the 2024 Annual Meeting of Stockholders to Be Held on June 5, 2024 . The Proxy Statement and Annual Report for the year ended December 31, 2023 are available at www.proxyvote.com .
Forward-Looking Statements. The Proxy Statement may contain forward-looking statements within the meaning of the
Forward-Looking Statements. The Proxy Statement may contain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements other than statements of historical fact included in the Proxy Statement are forward-looking statements, including statements about the Companys Board of Directors, corporate governance practices, executive compensation program, equity compensation utilization and environment, social and governance initiatives. In some cases, you can identify forward-looking statements by terms such as may, might, will, objective, intend, should, could, can, would, expect, believe, design, estimate, predict, potential, plan or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in the Proxy Statement. Such risks, uncertainties and other factors include those identified in the Companys Annual Report on Form 10-K for the year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (SEC) and other subsequent documents we file with the SEC. The Company expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law. Website References. Website references throughout this document are inactive textual references and provided for convenience only, and the content on the referenced websites is not incorporated herein by reference and does not constitute a part of the Proxy Statement. Table of Contents 275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF S